Objective To explore the clinical efficacy of immunotherapy combined with chemotherapy in the treat-ment of advanced non-small cell lung cancer (NSCLC). Method 186 patients with advanced NSCLC were enrolled in the study, and were randomized as study group, receiving immunotherapy+chemotherapy (n=98), and control group, ad-ministered with chemotherapy alone (n=88);the score of clinical symptom, clinical efficacy, immune function and the ad-verse reactions in the two groups were observed. The long-term survival of both groups were compared during 2-year fol-low-up. Result The study group had a significantly lower score of clinical symptom, and higher clinical response rate and benefit rate compared with those of the control group (P<0.05). The proportion of T lymphocyte subsets in peripheral blood was higher in study group than that in control group after treatment, with significant difference observed (P<0.01). The incidences of adverse reactions were comparable between the two groups (P>0.05). The 2-year survival rate and me-dian survival time were all significantly higher in study group compared with that in control group in the 2-year follow up (P<0.05). Conclusion Immunotherapy combined with chemotherapy is fairly effective in improving clinical symptoms, increasing efficacy of chemotherapy and immune function, which is of important clinical value in the treatment of non-small cell lung cancer.%目的：探讨免疫治疗联合化疗在中晚期非小细胞肺癌（NSCLC）治疗中的疗效。方法将186例中晚期NSCLC患者作为研究对象，按照分层随机分组法将患者分为两组，对照组88例给予单纯化疗，观察组98例给予免疫治疗联合化疗，观察两组患者临床症状积分、临床疗效、免疫功能及不良反应发生率。随访2年，比较两组患者远期生存情况。结果治疗后观察组临床症状积分明显低于对照组，而临床有效率及受益率高于对照组，差异均有统计学意义（P﹤0.01）。治疗后观察组外周血T淋巴细胞亚群比例明显高于对照组，差异有统计学意义（P﹤0.01）。两组患者不良反应发生率比较，差异无统计学意义（P﹥0.05）。随访2年，观察组患者2年生存率及中位生存时间高于对照组，差异有统计学意义（P﹤0.05）。结论免疫治疗联合化疗能有效缓解患者临床症状，提高临床化疗效果及免疫功能，在中晚期非小细胞肺癌治疗中具有较高应用价值。
展开▼
